SEP
PPH icon

Signature Equity Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

Signature Equity Partners’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39
Closed -$4.02K – 1628
2025
Q4 		$4.02K Buy
+39
New +$3.79K ﹤0.01% 1045

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $16B AUM 37.57% 1-Year Est. Return
ERSOT
Employees Retirement System of Texas Austin, Texas $12.6B AUM 31.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

Signature Equity Partners's PPH Position: Q1 2026 in Review

Signature Equity Partners sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2026, closing a stake of 39 shares — an estimated $4.02K sold.

Signature Equity Partners first reported a position in PPH in Q4 2025 and held it in 1 quarter. The position peaked at $4.02K in Q4 2025. 148 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

  • Signature Equity Partners reported no remaining VanEck Pharmaceutical ETF position as of Q1 2026 after selling out during the quarter.
  • Signature Equity Partners sold 39 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $4.02K.
  • Signature Equity Partners first reported a position in VanEck Pharmaceutical ETF in Q4 2025 and held it in 1 quarter.
  • Signature Equity Partners's VanEck Pharmaceutical ETF position peaked at $4.02K in Q4 2025.
  • 148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.